Health Catalyst (NASDAQ:HCAT) PT Lowered to $21.00 at Piper Sandler

Health Catalyst (NASDAQ:HCATGet Rating) had its price target dropped by equities researchers at Piper Sandler from $38.00 to $21.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Piper Sandler’s price target points to a potential upside of 62.16% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. Canaccord Genuity Group decreased their target price on shares of Health Catalyst from $62.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, March 2nd. Jefferies Financial Group raised shares of Health Catalyst from a “hold” rating to a “buy” rating and decreased their target price for the company from $31.00 to $28.00 in a research note on Thursday, March 17th. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $66.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. BTIG Research cut their price target on shares of Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Friday, March 25th. Finally, SVB Leerink cut their price target on shares of Health Catalyst from $64.00 to $48.00 and set an “outperform” rating on the stock in a report on Wednesday, March 2nd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Health Catalyst presently has a consensus rating of “Buy” and an average price target of $36.23.

HCAT stock opened at $12.95 on Wednesday. Health Catalyst has a 1 year low of $12.53 and a 1 year high of $59.50. The firm has a 50-day moving average of $22.49 and a 200 day moving average of $32.50. The company has a market cap of $698.48 million, a P/E ratio of -4.03 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.46 and a quick ratio of 5.46.

Health Catalyst (NASDAQ:HCATGet Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. Health Catalyst had a negative net margin of 63.33% and a negative return on equity of 21.30%. The business had revenue of $68.09 million during the quarter, compared to the consensus estimate of $66.01 million. During the same quarter last year, the firm earned ($0.37) earnings per share. The business’s revenue for the quarter was up 21.9% on a year-over-year basis. On average, equities research analysts expect that Health Catalyst will post -1.8 earnings per share for the current fiscal year.

In related news, COO Paul Horstmeier sold 23,209 shares of the firm’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $25.30, for a total value of $587,187.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Daniel H. Orenstein sold 4,112 shares of the firm’s stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $26.82, for a total transaction of $110,283.84. The disclosure for this sale can be found here. Insiders sold 37,286 shares of company stock worth $934,979 in the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Fairfield Bush & CO. purchased a new position in shares of Health Catalyst during the 1st quarter worth $25,000. UMB Bank N A MO purchased a new position in shares of Health Catalyst during the 4th quarter worth $30,000. Manchester Capital Management LLC boosted its stake in shares of Health Catalyst by 667.5% during the 1st quarter. Manchester Capital Management LLC now owns 1,159 shares of the company’s stock worth $30,000 after acquiring an additional 1,008 shares during the last quarter. Sageworth Trust Co of South Dakota purchased a new position in shares of Health Catalyst during the 4th quarter worth $61,000. Finally, Advisor Group Holdings Inc. boosted its stake in shares of Health Catalyst by 27.3% during the 3rd quarter. Advisor Group Holdings Inc. now owns 1,466 shares of the company’s stock worth $73,000 after acquiring an additional 314 shares during the last quarter. Institutional investors and hedge funds own 97.53% of the company’s stock.

About Health Catalyst (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Featured Stories

The Fly logo

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.